“In that regard, we would now like
to inform you that we have received
an establishment inspection
report (EIR) from the USFDA as
the closure of audit for the above-
referred facility,” the drug maker
said its filing.
INDIAN R&D EFFORTS INTO
HEALTH & ENVIRONMENT ALL SET
TO GET A NEW BOOST
Research and development
efforts in the areas of health and
environment
are set to
get a major
boost
with the
Government
of India
becoming
an Associate Member of European
Union’s cutting edge Synchrotron
Radiation Facility (ESRF) at
Grenoble in France.
The agreement will be for a period
of three years at a cost of Rs
17.5 crore. It will provide Indian
scientific community access to
multiple beam lines and other
cutting edge facilities. India is the
22nd country to join the Facility.
The agreement builds up on
the success of a previous ad-
hoc arrangement signed by the
Department of Biotechnology
(DBT) with European Molecular
Biology Laboratory (EMBL) in
2008 to access a beam line called
BM14 at the Facility. The project
was implemented by the New
Delhi based National Institute of
Immunology (NII) in partnership
with EMBL.
Under the new arrangement,
that was formally launched in
the presence of the Minister for
Science and Technology, Harsh
Vardhan on June 19, India
became a scientific partner of
ESRF through the Regional
Centre for Biotechnology (RCB),
Faridabad.
three observations.
ASTRAZENECA GETS DCGI’S
APPROVAL FOR ASTHMA DRUG,
SYMBICORT 320
AstraZeneca Pharma India
Limited (AstraZeneca India), a
leading global biopharmaceutical
company has received marketing
authorisation from the Drug
Controller General of India (DCGI)
for Symbicort 320 mcg. The drug a
fixed-dose combination comprising
budesonide and formoterol
BIOVOICENEWS.COM
59